HEPA.US Hepion Pharmaceuticals Inc

Healthcare Pharmaceuticals USA Stocks
0.1140 USD
Close of Nov 15, 2026
0.0340 0.2100
Market cap
USD 14.0M
P/E
-
P/B
41.86x
ROE
-322.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is HEPA.US undervalued?

Graham number

The Graham number of Hepion Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hepion Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Hepion Pharmaceuticals Inc yet.

Hepion Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosi…

Full company profile